Back to Journals » OncoTargets and Therapy » Volume 14

Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline MET Exon 14 Skipping Mutation: A Case Report

Authors Jiao Y, Fang C, Yang Y, Shao L, Huang Y, Sun Q, Dong Y

Received 5 January 2021

Accepted for publication 11 March 2021

Published 7 April 2021 Volume 2021:14 Pages 2417—2421


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr William Cho

Yang Jiao,1,* Chen Fang,1,* Yuchen Yang,2 Lin Shao,2 Yi Huang,1 Qinying Sun,1 Yuchao Dong1

1Pulmonary and Critical Care Medicine, Changhai Hospital, The Naval Medical University, Guangzhou, People’s Republic of China; 2Burning Rock Biotech, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Yuchao Dong; Qinying Sun
Pulmonary and Critical Care Medicine, Changhai Hospital, The Naval Medical University, #168 Changhai Road, Yangpu District, Shanghai, 200433, People’s Republic of China
Email [email protected]; [email protected]

Abstract: MET exon 14 skipping variants have been identified as a novel type of oncogenic driver mutations in non-small-cell lung cancer (NSCLC), while the germline MET mutation, especially germline MET exon 14 skipping mutation rarely occurred in NSCLC. Herein, we present the first case of a 33-year-old NSCLC patient with a germline MET exon 14 skipping mutation, who also harbored a somatic EGFR exon 20 insertion. The patient was initially diagnosed with a stage IIB adenosquamous carcinoma. He underwent a thoracoscopic radical resection followed by four cycles of adjuvant chemotherapy but relapsed 2 months after completing the chemotherapy. Afatinib was then prescribed but disease progressed immediately. Subsequently, he received anlotinib but did not respond and died a month later with an overall survival of 9 months. Our case may provide an evidence for the pathogenicity of germline MET exon 14 skipping mutation in NSCLC and suggest it as an adverse prognostic factor.

Keywords: MET exon 14 skipping mutation, rare germline mutation, next-generation sequencing, NGS, lung adenosquamous carcinoma, rapid disease progression

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]